(Total Views: 563)
Posted On: 08/26/2020 10:06:33 AM
Post# of 153859
I'll agree to disagree.
We had many thousands receiving HCQ and azithromycin over the past six months. Double blinded trials were slow to be conducted with poor control of defined patient populations (mild/moderate/severe/critical), dosing and time of administration.
So all we know is that these are not effective when patients are severe/critical. Are they effective in prevention and early/virologic stages?
We still don't know.
I am quite aware this disease rages on and that solutions are needed.
If we expect worldwide adoption of leronlimab with federal agencies providing the many billions of dollars needed to treat more than a few thousand patients, there must be hard evidence.
That is provided by rigorous trials.
Not open label. Not anecdotal.
Evidence based medicine needs evidence.
We could have had expanded access since April, but at the cost of the evidence which has now been provided by CD10 and that is upcoming from CD12.
OWS and marshaling the resources of BARDA for a pink sheet company's HIV drug, which has approval for nothing is, IMO, the appropriate way to think outside the box while still thinking in a logical and scientifically valid manner.
We had many thousands receiving HCQ and azithromycin over the past six months. Double blinded trials were slow to be conducted with poor control of defined patient populations (mild/moderate/severe/critical), dosing and time of administration.
So all we know is that these are not effective when patients are severe/critical. Are they effective in prevention and early/virologic stages?
We still don't know.
I am quite aware this disease rages on and that solutions are needed.
If we expect worldwide adoption of leronlimab with federal agencies providing the many billions of dollars needed to treat more than a few thousand patients, there must be hard evidence.
That is provided by rigorous trials.
Not open label. Not anecdotal.
Evidence based medicine needs evidence.
We could have had expanded access since April, but at the cost of the evidence which has now been provided by CD10 and that is upcoming from CD12.
OWS and marshaling the resources of BARDA for a pink sheet company's HIV drug, which has approval for nothing is, IMO, the appropriate way to think outside the box while still thinking in a logical and scientifically valid manner.
(6)
(0)
